NCT02754011 - Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 2, 2017

Primary Completion Date

February 28, 2022

Study Completion Date

December 23, 2022

Conditions

Breast Cancer

Interventions

DRUG

Combination of ribociclib + capecitabine

RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment

Trial Locations (2)

Unknown

Centre Leon Berard, Lyon

Institut de Cancérologie de l'Ouest, Saint-Herblain